Loading market dashboard
Taysha Gene Therapies, Inc.
TSHAHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
DALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 714,700 shares of the Company's common stock and an option to purchase 468,600 shares of the Company's common stock in connection with their employment.
DALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 714,700 shares of the Company's common stock and an option to purchase 468,600 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
Taysha Gene Therapies is now a one-drug company, fully reliant on TSHA-102 for Rett syndrome after discontinuing its previous pipeline. I rate TSHA as a Buy, citing strong cash reserves, promising early TSHA-102 data, and an accelerated FDA pathway skipping Phase 3. TSHA-102's miRARE technology offers a safety edge over competitor NGN-401, with pivotal data expected in late 2026 and potential commercialization by 2027/2028.
Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript
DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update.
DALLAS, May 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on May 1, 2026, the Compensation Committee of Taysha's Board of Directors granted five new employees, in the aggregate, restricted stock units (RSUs) representing 188,000 shares of the Company's common stock in connection with their employment. The RSUs were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
DALLAS, April 29, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2026, and host a corporate update conference call and webcast on Wednesday, May 6, 2026, at 8:30 AM Eastern Time.
In vitro data demonstrated self-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 (ssAAV9), supporting the ability to effectively deliver TSHA-102 to the CNS by lumbar IT administration
Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA - Get Free Report) were up 6.9% during mid-day trading on Monday after Canaccord Genuity Group raised their price target on the stock from $14.00 to $17.00. Canaccord Genuity Group currently has a buy rating on the stock. Taysha Gene Therapies traded as high as $4.64 and last
Capricorn Fund Managers Ltd purchased a new stake in Taysha Gene Therapies, Inc. (NASDAQ: TSHA) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 300,000 shares of the company's stock, valued at approximately $1,650,000. Capricorn Fund Managers Ltd
DALLAS, April 03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on April 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 300,000 shares of the Company's common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
Taysha Gene Therapies (NASDAQ: TSHA) highlighted clinical, regulatory, and commercial progress for its lead Rett syndrome gene therapy program while also reporting higher operating expenses and a wider net loss for full-year 2025, according to management on the company's March 19 conference call. TSHA-102 development advances with FDA alignment and pivotal trial underway Chief Executive Officer
Taysha Gene Therapies, Inc. (NASDAQ: TSHA - Get Free Report) gapped up prior to trading on Thursday following a better than expected earnings announcement. The stock had previously closed at $4.45, but opened at $4.55. Taysha Gene Therapies shares last traded at $4.5150, with a volume of 715,255 shares traded. The company reported ($0.08) earnings per
Taysha Gene Therapies, Inc. (TSHA) Q4 2025 Earnings Call Transcript
Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026
Ally Bridge Group NY LLC acquired a new position in shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) during the undefined quarter, according to its most recent 13F filing with the SEC. The fund acquired 1,898,112 shares of the company's stock, valued at approximately $6,207,000. Taysha Gene Therapies comprises 3.8% of Ally Bridge
DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2025, and host a corporate update conference call and webcast on Thursday, March 19, 2026, at 8:30 AM Eastern Time. Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha's website at ir.tayshagtx.com.
